From the ranking of hospital diagnosis and treatment and drug sales data in various provinces, look at the enterprise sales plan in 2023

At the end of the year, how to plan the market for next year, and how to distribute sales indicators and assessment data in each market? Here, from the two dimensions of medical services and drug circulation and sales data, it brings you some thoughts, I hope it will help
you.

Text: Point Crane

Recently, the National Health Commission announced the patient fees of secondary and above public hospitals nationwide from January to June 2022, as well as the national medical service situation
.
Through the data, let's take a look at some changes
in the medical and pharmaceutical markets.

From January to June 2022, the average outpatient cost of tertiary public hospitals in China increased slightly (+1.
7%, at comparable prices, the same below), but the average inpatient cost decreased (-5.
5%); The average outpatient and inpatient expenses of secondary public hospitals decreased by 2%.

In terms of service volume, the number of consultations and treatments in tertiary public hospitals increased by only 0.
4%, and the number of discharges increased by 5%, but the average inpatient cost decreased by 5.
5%, and the increase in inpatient numbers offset the average inpatient cost, and the overall inpatient cost of tertiary public hospitals should remain unchanged or increase slightly
.
The number of discharges from secondary public hospitals fell by 5.
3%, and it seems that hospitalizations in the first half of this year are running to large hospitals, and the performance of secondary hospitals should decline
.
From the perspective of the volume of medical services in various regions, the total number of consultations and treatments in medical institutions nationwide was 3.
16 billion, of which 19.
6 were in hospitals, which was basically unchanged
year-on-year.
Among them, Guangdong ranks first in the country with 189 million person-times, Zhejiang ranks second with about 149 million person-times, and the number of diagnosis and treatment in Shandong, Sichuan, Jiangsu, Henan and Sichuan provinces is more than 120 million, which is not only related to the population base of each province, but also related to the medical resources and service capacity
of each province.
If the ratio obtained by dividing the number of consultations and the number of people in each region is used as a measure of the efficiency of local medical services (the larger the ratio, indicating that the local medical visits are more frequent, or the number of people visiting from other places is large), the above ranking may be adjusted to Zhejiang, Guangdong, Sichuan, Jiangsu, Shandong, and Henan
.
As follows:

As shown in the figure above, the number of hospital consultations in Zhejiang is 2.
29 times that of the province's population, which is much higher than that of other provinces, with Guangdong, Sichuan and Jiangsu accounting for about 1.
5 times, while the two northern provinces of Shandong and Henan are about
1.
25 times.
But the above data is only partial, if from the perspective of the whole country, Beijing and Shanghai are the super kings, the ratio of hospital consultations and treatments to the number of local population is 3.
01 times and 2.
86 times respectively, which shows that Beijing and Shanghai are the Beijing and Shanghai
of the people of the whole country.

In the newly released Fudan version of the 2021 comprehensive list of national hospital rankings, the first and third places are in Beijing (Union Hospital and 301 Hospital), while among the top ten, there are 3 hospitals in Shanghai, 13 in Beijing and 9 in Shanghai in the top 100 comprehensive list, reflecting the strong medical resources
of the two places.

The concentration of medical resources is similar to the industrial cluster of manufacturing, requiring experts to have experts, patients to have patients, and various medical technologies and clinical resources can be efficiently integrated and transmitted
.
For enterprises, clinical trials of drugs and medical devices can be carried out efficiently, pre-market research of new products can be guaranteed, and effective use, observation, promotion and dissemination
can be obtained after marketing.
Therefore, for innovative drugs, such areas with high ratios are worth investing; For conventional drugs, due to the high-density population in Beijing, Shanghai, Jiangsu, Zhejiang and Guangdong, as well as the relatively high proportion of the elderly population structure, drugs for common diseases and chronic diseases can be rapidly increased
.

Of course, due to the different product structure of enterprises, it is not possible to rely solely on the above indicators to measure a market
.
At this time, the data of pharmaceutical circulation of the Ministry of Commerce can be introduced for reference
.
The "2021 Statistical Analysis Report on the Operation of the Pharmaceutical Circulation Industry" released by the Ministry of Commerce announced the ranking of pharmaceutical sales by province and the ranking list of the top 100 pharmaceutical businesses in 2021
.
According to 2021, the sales of the six major regions in the country accounted for 36.
2% of the total national sales: 36.
2% in East China, 27.
1% in Central and South China, 15.
0% in North China, 13.
3% in Southwest China, 4.
3% in Northeast China, and 4.
1%
in Northwest China.
Among them, the sales of the three major regions of East China, Central South China and North China accounted for 78.
3% of the total national sales, basically the same
as the previous year.
By province and region, the top 10 provinces in terms of sales in 2021 are: Guangdong, Beijing, Shanghai, Jiangsu, Zhejiang, Shandong, Henan, Anhui, Sichuan, and Hubei
.
Compared with 2020, the ranking of provinces remained stable; The sales of the above provinces and cities accounted for 65.
2% of the total national sales, down 0.
1 percentage points
year-on-year.

The top rankings are actually highly correlated with hospital diagnosis and treatment data, and they are still those familiar provinces and cities
.
Depending on the market situation, enterprises should develop different marketing plans
under the overall strategic framework.

In resource-intensive markets, expectations will be much higher, but the resources invested are also high-quality, "high-density" talents, and capital + talents are intensive
.
Beijing and Shanghai are domestic medical highlands, academic highlands and policy highlands, whether it is R&D, registration, market access and sales models, the two cities can find suitable resources to integrate to achieve the goal
.
The development of Beijing and Shanghai will drive the first- and second-tier cities of Guangzhou, Nanjing, Hangzhou, Wuhan and Chengdu, and the above-mentioned central cities will then drive the third- and fourth-tier cities in the province to form regional coverage
.

In markets with a large population size but average medical resources, the wide coverage of resources rather than high density should be considered, and the advantages of channels should be used to obtain or the model
with higher input and output.
For example, Henan, Shandong, and some cities with large populations, such as Linyi, Nanyang, Xuzhou, Fuyang, etc
.

In the sparsely populated western region, enterprises generally do not invest too many resources, but should choose to carry out radiation in hub cities, such as Chengdu radiating Tibet, Xi'an and Lanzhou radiating Shaanxi-Gansu-Ningqing, and Urumqi and Kashgar radiating Xinjiang
.

The following is the total regional sales statistics in 2021, you can slowly compare the diagnosis and treatment data to find the relationship between
population, medical resources and economic society.

Attached: Data released by the National Health Commission from January to June 2022